» Articles » PMID: 28531338

Placental Exosomes As Early Biomarker of Preeclampsia: Potential Role of Exosomal MicroRNAs Across Gestation

Overview
Specialty Endocrinology
Date 2017 May 23
PMID 28531338
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

Context: There is a need to develop strategies for early prediction of patients who will develop preeclampsia (PE) to establish preventive strategies to reduce the prevalence and severity of the disease and their associated complications.

Objective: The objective of this study was to investigate whether exosomes and their microRNA cargo present in maternal circulation can be used as early biomarker for PE.

Design, Setting, Patients, And Interventions: A retrospective stratified study design was used to quantify total exosomes and placenta-derived exosomes present in maternal plasma of normal (n = 32 per time point) and PE (n = 15 per time point) pregnancies. Exosomes present in maternal circulation were determined by nanoparticle tracking analysis. An Illumina TruSeq® Small RNA Library Prep Kit was used to construct a small RNA library from exosomal RNA obtained from plasma samples.

Results: In presymptomatic women, who subsequently developed PE, the concentration of total exosomes and placenta-derived exosomes in maternal plasma was significantly greater than those observed in controls, throughout pregnancy. The area under the receiver operating characteristic curves for total exosome and placenta-derived exosome concentrations were 0.745 ± 0.094 and 0.829 ± 0.077, respectively. In total, over 300 microRNAs were identified in exosomes across gestation, where hsa-miR-486-1-5p and hsa-miR-486-2-5p were identified as the candidate microRNAs.

Conclusions: Although the role of exosomes during PE remains to be fully elucidated, we suggest that the concentration and content of exosomes may be of diagnostic utility for women at risk for developing PE.

Citing Articles

Exploring the link between M1 macrophages and EMT of amniotic epithelial cells: implications for premature rupture of membranes.

Gao Y, Zhang Y, Mi N, Miao W, Zhang J, Liu Y J Nanobiotechnology. 2025; 23(1):163.

PMID: 40033278 PMC: 11877754. DOI: 10.1186/s12951-025-03192-6.


Rapid and high-sensitivity screening of pregnancy complications by profiling circulating placental extracellular vesicles.

Palma C, Masud M, Guanzon D, Lai A, Razo M, Nakahara A Sci Adv. 2025; 11(9):eadr4074.

PMID: 40009685 PMC: 11864196. DOI: 10.1126/sciadv.adr4074.


Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).

Paton M, Benders M, Blatch-Williams R, Dallimore E, Edwards A, Elwood N Pediatr Res. 2025; .

PMID: 39815092 DOI: 10.1038/s41390-025-03856-x.


Assessment of NanoString technology as a tool for profiling circulating miRNA in maternal blood during pregnancy.

Adamova P, Powell A, Dykes I Extracell Vesicles Circ Nucl Acids. 2024; 5(3):471-496.

PMID: 39697629 PMC: 11648433. DOI: 10.20517/evcna.2024.38.


Mucosal Exosome Proteomics of Hybrid Grouper ♀ × ♂ Infected by .

Yang D, Ma X, Zhong S, Guo J, Cheng D, Chen X Animals (Basel). 2024; 14(23).

PMID: 39682367 PMC: 11640173. DOI: 10.3390/ani14233401.